Ovid Therapeutics Inc. · NASDAQ:OVID

Ovid Therapeutics — Investor Presentation (April 2021)

18 slides from Ovid Therapeutics's investor presentation, Apr 19, 2021

1. Slide 1: Ovid Therapeutics Corporate Overview

   Ovid Therapeutics Corporate Overview April 19, 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1 January 2021 April 2021 Exhibit 99.1

2. Slide 2: Disclaimers and Forward-Looking Statements

   Disclaimers and Forward-Looking Statements ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “believe,” “expect,” “plan,” “anticipate” and s

3. Slide 3: Clear Vision Supported by a Strong Foundation

   ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 3 boldvision Ovid is uniquely positioned to change the treatment paradigm for patients with severe rare neurological diseases Innovation Patients Expertise Translating novel scientific approaches to create customized solutions for rare disease Commi

4. Slide 4: Pipeline Focused on Advancing Treatment of Rare Diseases

   Phase 3 Planned Initiation 1H 2021 Phase 3 Planned Initiation 1H 2021 Anticipate filing three INDs in three years, beginning 1H 2022 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 4 January 2021 April 2021 Pipeline Focused on Advancing Treatment of Rare Diseases

5. Slide 5: Transformative $856M+ Agreement with Takeda

   5 April 2021 2017 Collaboration Global for all soticlestat indications 2021 Agreement Global for all soticlestat indications Ovid receives up to $856M in payments and double-digit royalties up to 20% on global sales Received $196M upfront (1Q ’21) Up to $660M in regulatory and commercial milestones

6. Slide 6: 2021 Strategic Priorities and Execution

   2021 Strategic Priorities and Execution ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 6 April 2021 Accelerate pre-clinical assets and anticipate filing three INDs from 2022 to 2025 Enhance clinical pipeline with complementary BD opportunities Access leading technologies to accelerate genetic me

7. Slide 7: Advance Next-Generation Neuroscience Pipeline

   Focus on ecosystem of rare neurological diseases with high unmet need Develop novel first-in-class / best-in-class therapeutics Create a customized disease approach leveraging deep understanding of underlying pathology Collaborate with the patient community, KOLs, and other external innovators to ac

8. Slide 8: OV329: Highly Potent Inhibitor of GABA Aminotransferase

   OV329: Highly Potent Inhibitor of GABA Aminotransferase ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 8 April 19, 2021 Mechanism: Highly potent GABA aminotransferase (GABA-AT) oral small molecule inhibitor Development status: IND enabling studies are underway, IND expected 1H 2022 Opportunity:

9. Slide 9: OV329 Appears Active in Models of Drug-Resistant Seizures

   OV329 Appears Active in Models of Drug-Resistant Seizures ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 9 April 19, 2021 April 2021 NMDA Model described by Shi et al., 2014 (PMID 26600368) OV329 pre-clinical NMDA model of infantile spasms demonstrates substantial anti-seizure activity OV329 v.

10. Slide 10: OV882: Potential Disease-Modifying Genetic Therapy for Angelman Syndrome

    OV882: Potential Disease-Modifying Genetic Therapy for Angelman Syndrome (AS) ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 10 April 19, 2021 April 2021 Mechanism: Short hairpin RNA that interacts with non-coding RNA to inhibit the silencing of paternal UBE3A gene Development status: POC* activ

11. Slide 11: OV882 Approach to the Treatment of Angelman Syndrome

    OV882 Approach to the Treatment of Angelman Syndrome ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 11 April 19, 2021 April 2021 DESCRIPTION OF APPROACH BENEFITS AND DRAWBACKS RNAI APPROACHES TO TREATING ANGELMAN SYNDROME DISEASE STATE ASO APPROACH Angelman syndrome is caused by a mutation in th

12. Slide 12: OV882 Appears Active in AS Neuron Cell Model

    OV882 Appears Active in AS Neuron Cell Model ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 12 April 19, 2021 April 2021 SCRAM shRNA OV882 UBE3A-ATS UBE3A mRNA Relative RNA Expression shRNA-OV882 Effects on UBE3A-Antisense and UBE3A Expression (iPSC-AS neurons) OV882 demonstrates activity in AS

13. Slide 13: OV815: Potential Advanced Genetic Therapy for KAND and Other KIF-associated Diseases

    OV815: Potential Advanced Genetic Therapy for KAND and Other KIF-associated Diseases ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 13 April 19, 2021 April 2021 Mechanism: Genetic/molecular approach targeting KIF1A Development status: Currently in screening stage for aptamer and gene silencing t

14. Slide 14: OV815 Has Potential For Broader Applicability Within the Kinesin Superfamily

    OV815 Has Potential For Broader Applicability Within the Kinesin Superfamily ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 14 April 19, 2021 KIF1A (Kinesin 3 Family Member) April 2021 Impact of KIF1A on neurotransmission KIF1A is a motor protein that transports cargo for neurons Disruption of c

15. Slide 15: Complementary BD Opportunities

    Components of BD activities ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 15 January 2021 April 2021 Complementary BD Opportunities 1. Disciplined and strategic approach assessing novel assets 3. Leverages our capabilities 2. Complements programs and strategy to existing pipeline 2

16. Slide 16: Strong Balance Sheet Supports Strategy

    Strong Balance Sheet Supports Strategy ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 16 April 19, 2021 April 2021 Strong balance sheet: Pro forma cash of over $250M* No debt Expected 2Q 2021 - 4Q 2021 quarterly OpEx of $8M-$10M (excluding non-cash expenses) 69M shares outstanding (as of 3-15-21

17. Slide 17: Leadership Team With Deep Knowledge and Expertise

    ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 17 Jeremy Levin DPhil, MB Bchir Chairman, CEO Amit Rakhit MD, MBA President, CMO Jason Tardio MBA Chief Commercial Officer Jeffrey Rona Chief Business Officer Thomas Perone JD, MBA GC, Corporate Secretary, and CCO Holly Roberts MD Vice President, Me

18. Slide 18: Thank you

    Thank you April 19, 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 18 January 2021 April 2021

Ovid Therapeutics — Investor Presentation (April 2021) on 6ix